Novavax, Inc. (NVAX)
USD 6.41
(0.0%)
USD 6.41
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.85 Billion USD | -17.86% |
| 2022 | 2.25 Billion USD | -12.34% |
| 2021 | 2.57 Billion USD | 62.83% |
| 2020 | 1.58 Billion USD | 814.96% |
| 2019 | 172.95 Million USD | -16.84% |
| 2018 | 207.97 Million USD | -31.25% |
| 2017 | 302.49 Million USD | -23.28% |
| 2016 | 394.3 Million USD | 2.14% |
| 2015 | 386.03 Million USD | 39.87% |
| 2014 | 276 Million USD | 16.98% |
| 2013 | 235.93 Million USD | 130.53% |
| 2012 | 102.34 Million USD | 53.73% |
| 2011 | 66.57 Million USD | -11.05% |
| 2010 | 74.84 Million USD | -12.57% |
| 2009 | 85.6 Million USD | 11.72% |
| 2008 | 76.62 Million USD | -16.07% |
| 2007 | 91.29 Million USD | -25.1% |
| 2006 | 121.87 Million USD | 44.43% |
| 2005 | 84.38 Million USD | 8.19% |
| 2004 | 77.99 Million USD | -7.33% |
| 2003 | 84.15 Million USD | 46.35% |
| 2002 | 57.5 Million USD | -14.32% |
| 2001 | 67.11 Million USD | 18.73% |
| 2000 | 56.52 Million USD | 1156.2% |
| 1999 | 4.5 Million USD | 18.42% |
| 1998 | 3.8 Million USD | -44.12% |
| 1997 | 6.8 Million USD | 19.3% |
| 1996 | 5.7 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.35 Billion USD | -27.05% |
| 2024 Q2 | 1.81 Billion USD | 34.36% |
| 2023 Q1 | 1.54 Billion USD | -31.7% |
| 2023 Q4 | 1.85 Billion USD | 11.96% |
| 2023 Q3 | 1.65 Billion USD | -1.66% |
| 2023 Q2 | 1.68 Billion USD | 9.23% |
| 2023 FY | 1.85 Billion USD | -17.86% |
| 2022 FY | 2.25 Billion USD | -12.34% |
| 2022 Q3 | 2.26 Billion USD | -13.56% |
| 2022 Q4 | 2.25 Billion USD | -0.39% |
| 2022 Q1 | 2.83 Billion USD | 10.02% |
| 2022 Q2 | 2.62 Billion USD | -7.47% |
| 2021 Q4 | 2.57 Billion USD | 0.42% |
| 2021 FY | 2.57 Billion USD | 62.83% |
| 2021 Q1 | 2.6 Billion USD | 64.83% |
| 2021 Q2 | 2.74 Billion USD | 5.41% |
| 2021 Q3 | 2.56 Billion USD | -6.68% |
| 2020 FY | 1.58 Billion USD | 814.96% |
| 2020 Q3 | 944.02 Million USD | 1.27% |
| 2020 Q2 | 932.22 Million USD | 184.16% |
| 2020 Q1 | 328.06 Million USD | 89.68% |
| 2020 Q4 | 1.58 Billion USD | 67.63% |
| 2019 Q1 | 221.31 Million USD | 6.41% |
| 2019 FY | 172.95 Million USD | -16.84% |
| 2019 Q4 | 172.95 Million USD | 4.94% |
| 2019 Q3 | 164.81 Million USD | -12.98% |
| 2019 Q2 | 189.38 Million USD | -14.43% |
| 2018 FY | 207.97 Million USD | -31.25% |
| 2018 Q1 | 276.06 Million USD | -8.74% |
| 2018 Q2 | 285.8 Million USD | 3.53% |
| 2018 Q3 | 250.47 Million USD | -12.36% |
| 2018 Q4 | 207.97 Million USD | -16.97% |
| 2017 Q1 | 361.5 Million USD | -8.32% |
| 2017 Q4 | 302.49 Million USD | -9.45% |
| 2017 Q3 | 334.07 Million USD | -6.08% |
| 2017 FY | 302.49 Million USD | -23.28% |
| 2017 Q2 | 355.7 Million USD | -1.6% |
| 2016 FY | 394.3 Million USD | 2.14% |
| 2016 Q4 | 394.3 Million USD | -14.21% |
| 2016 Q2 | 525 Million USD | -11.39% |
| 2016 Q1 | 592.5 Million USD | 53.48% |
| 2016 Q3 | 459.62 Million USD | -12.45% |
| 2015 FY | 386.03 Million USD | 39.87% |
| 2015 Q1 | 438.84 Million USD | 59.0% |
| 2015 Q4 | 386.03 Million USD | -4.6% |
| 2015 Q2 | 424.69 Million USD | -3.22% |
| 2015 Q3 | 404.63 Million USD | -4.72% |
| 2014 Q4 | 276 Million USD | -5.64% |
| 2014 FY | 276 Million USD | 16.98% |
| 2014 Q3 | 292.51 Million USD | -6.24% |
| 2014 Q2 | 311.99 Million USD | 42.72% |
| 2014 Q1 | 218.59 Million USD | -7.35% |
| 2013 Q3 | 245.07 Million USD | 163.75% |
| 2013 FY | 235.93 Million USD | 130.53% |
| 2013 Q4 | 235.93 Million USD | -3.73% |
| 2013 Q2 | 92.91 Million USD | -5.86% |
| 2013 Q1 | 98.7 Million USD | -3.56% |
| 2012 Q4 | 102.34 Million USD | 27.06% |
| 2012 Q1 | 68.63 Million USD | 3.1% |
| 2012 FY | 102.34 Million USD | 53.73% |
| 2012 Q2 | 76.97 Million USD | 12.15% |
| 2012 Q3 | 80.54 Million USD | 4.64% |
| 2011 FY | 66.57 Million USD | -11.05% |
| 2011 Q1 | 70.13 Million USD | -6.29% |
| 2011 Q2 | 69.34 Million USD | -1.13% |
| 2011 Q3 | 67.08 Million USD | -3.26% |
| 2011 Q4 | 66.57 Million USD | -0.76% |
| 2010 Q2 | 68.94 Million USD | -8.53% |
| 2010 Q3 | 79.31 Million USD | 15.04% |
| 2010 Q4 | 74.84 Million USD | -5.64% |
| 2010 Q1 | 75.37 Million USD | -11.95% |
| 2010 FY | 74.84 Million USD | -12.57% |
| 2009 Q4 | 85.6 Million USD | 12.82% |
| 2009 FY | 85.6 Million USD | 11.72% |
| 2009 Q1 | 67.96 Million USD | -11.31% |
| 2009 Q3 | 75.88 Million USD | 3.63% |
| 2009 Q2 | 73.22 Million USD | 7.74% |
| 2008 FY | 76.62 Million USD | -16.07% |
| 2008 Q2 | 80.77 Million USD | -6.31% |
| 2008 Q1 | 86.22 Million USD | -5.55% |
| 2008 Q3 | 89.51 Million USD | 10.82% |
| 2008 Q4 | 76.62 Million USD | -14.4% |
| 2007 Q4 | 91.29 Million USD | -8.44% |
| 2007 Q3 | 99.7 Million USD | -7.71% |
| 2007 Q2 | 108.03 Million USD | -6.37% |
| 2007 FY | 91.29 Million USD | -25.1% |
| 2007 Q1 | 115.39 Million USD | -5.32% |
| 2006 Q3 | 125.38 Million USD | -3.98% |
| 2006 Q4 | 121.87 Million USD | -2.79% |
| 2006 Q1 | 135.43 Million USD | 60.5% |
| 2006 FY | 121.87 Million USD | 44.43% |
| 2006 Q2 | 130.57 Million USD | -3.59% |
| 2005 FY | 84.38 Million USD | 8.19% |
| 2005 Q3 | 60.54 Million USD | 0.41% |
| 2005 Q4 | 84.38 Million USD | 39.37% |
| 2005 Q2 | 60.29 Million USD | -9.43% |
| 2005 Q1 | 66.57 Million USD | -14.64% |
| 2004 FY | 77.99 Million USD | -7.33% |
| 2004 Q2 | 74.61 Million USD | -5.31% |
| 2004 Q1 | 78.8 Million USD | -6.37% |
| 2004 Q3 | 87.6 Million USD | 17.4% |
| 2004 Q4 | 77.99 Million USD | -10.97% |
| 2003 Q3 | 61.56 Million USD | -3.67% |
| 2003 Q4 | 84.15 Million USD | 36.7% |
| 2003 Q1 | 68.03 Million USD | 18.31% |
| 2003 FY | 84.15 Million USD | 46.35% |
| 2003 Q2 | 63.9 Million USD | -6.07% |
| 2002 Q3 | 62.22 Million USD | -11.17% |
| 2002 Q4 | 57.5 Million USD | -7.59% |
| 2002 FY | 57.5 Million USD | -14.32% |
| 2002 Q1 | 62.89 Million USD | -6.3% |
| 2002 Q2 | 70.04 Million USD | 11.38% |
| 2001 FY | 67.11 Million USD | 18.73% |
| 2001 Q1 | 54.33 Million USD | -3.89% |
| 2001 Q3 | 68.83 Million USD | 19.95% |
| 2001 Q2 | 57.38 Million USD | 5.61% |
| 2001 Q4 | 67.11 Million USD | -2.49% |
| 2000 Q1 | 18.87 Million USD | 319.51% |
| 2000 Q2 | 16.63 Million USD | -11.87% |
| 2000 Q3 | 14.48 Million USD | -12.93% |
| 2000 Q4 | 56.52 Million USD | 290.21% |
| 2000 FY | 56.52 Million USD | 1156.2% |
| 1999 FY | 4.5 Million USD | 18.42% |
| 1999 Q4 | 4.5 Million USD | 0.0% |
| 1999 Q3 | 4.5 Million USD | -18.18% |
| 1999 Q1 | 3 Million USD | -21.05% |
| 1999 Q2 | 5.5 Million USD | 83.33% |
| 1998 Q4 | 3.8 Million USD | -62.0% |
| 1998 FY | 3.8 Million USD | -44.12% |
| 1998 Q2 | 11.1 Million USD | -8.26% |
| 1998 Q1 | 12.1 Million USD | 77.94% |
| 1998 Q3 | 10 Million USD | -9.91% |
| 1997 Q2 | 8.6 Million USD | -9.47% |
| 1997 Q1 | 9.5 Million USD | 66.67% |
| 1997 FY | 6.8 Million USD | 19.3% |
| 1997 Q3 | 7.4 Million USD | -13.95% |
| 1997 Q4 | 6.8 Million USD | -8.11% |
| 1996 FY | 5.7 Million USD | 0.0% |
| 1996 Q4 | 5.7 Million USD | 7.55% |
| 1996 Q3 | 5.3 Million USD | -11.67% |
| 1996 Q1 | 6.8 Million USD | 0.0% |
| 1996 Q2 | 6 Million USD | -11.76% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Absci Corporation | 234.48 Million USD | -691.258% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -180.63% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 51.556% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -293658.273% |
| Apollomics, Inc. | 55.38 Million USD | -3249.779% |
| 180 Life Sciences Corp. | 5.25 Million USD | -35176.176% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -1827.588% |
| Bicycle Therapeutics plc | 595.34 Million USD | -211.642% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -764.937% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -2417.356% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -2364.981% |
| Chimerix, Inc. | 212.77 Million USD | -771.978% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 16.785% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -1322.961% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -422.361% |
| Fortress Biotech, Inc. | 167.52 Million USD | -1007.495% |
| Fortress Biotech, Inc. | 167.52 Million USD | -1007.495% |
| Gritstone bio, Inc. | 177.76 Million USD | -943.681% |
| Allakos Inc. | 243.61 Million USD | -661.603% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -1328.351% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -1374.319% |
| Cytokinetics, Incorporated | 824.31 Million USD | -125.077% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -2033.582% |
| Innoviva, Inc. | 1.24 Billion USD | -49.202% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -19388.317% |
| NLS Pharmaceutics AG | 1.84 Million USD | -100371.18% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -970.416% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -28068.762% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -590.959% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -1217.172% |
| ImmuCell Corporation | 43.8 Million USD | -4135.157% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -185.738% |
| Incyte Corporation | 6.78 Billion USD | 72.644% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -972.797% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -60060.52% |
| Mustang Bio, Inc. | 17.74 Million USD | -10357.344% |
| MiMedx Group, Inc. | 239.04 Million USD | -676.141% |
| MEI Pharma, Inc. | 41.37 Million USD | -4384.21% |
| MacroGenics, Inc. | 306.82 Million USD | -504.7% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -25159.385% |
| Mereo BioPharma Group plc | 66.49 Million USD | -2690.03% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -10732.601% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -985.579% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | -24.733% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -3160.671% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -8044.252% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -58317.569% |
| NextCure, Inc. | 129.41 Million USD | -1333.604% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -1848.643% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -3339.13% |
| Onconetix, Inc. | 88.82 Million USD | -1988.845% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -4951.436% |
| Opthea Limited | 188.79 Million USD | -882.748% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -1188.192% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -163776.452% |
| PDS Biotechnology Corporation | 59.39 Million USD | -3023.993% |
| Precigen, Inc. | 151.04 Million USD | -1128.354% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -4696.644% |
| Prime Medicine, Inc. | 193.85 Million USD | -857.097% |
| PureTech Health plc | 693.97 Million USD | -167.351% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -227.602% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 94.391% |
| Replimune Group, Inc. | 487.72 Million USD | -280.41% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -15092.02% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -1482.719% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -35788.768% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 11.168% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -9704.343% |
| Sesen Bio, Inc. | 189.17 Million USD | -880.76% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -1022.273% |
| Solid Biosciences Inc. | 164.93 Million USD | -1024.866% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -202.725% |
| SciSparc Ltd. | 11.18 Million USD | -16492.22% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -294.136% |
| TG Therapeutics, Inc. | 329.58 Million USD | -462.929% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -1101.203% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -22845.115% |
| Travere Therapeutics, Inc. | 788.91 Million USD | -135.177% |
| UroGen Pharma Ltd. | 178.31 Million USD | -940.509% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -2173.787% |
| XOMA Corporation | 234.3 Million USD | -691.863% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -230.116% |
| AbCellera Biologics Inc. | 1.48 Billion USD | -24.679% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -3559.668% |
| Cassava Sciences, Inc. | 151.66 Million USD | -1123.332% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -6462.38% |
| Precision BioSciences, Inc. | 159.78 Million USD | -1061.178% |
| Dyadic International, Inc. | 8.21 Million USD | -22473.169% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -10627.621% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -5745.438% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -1799.311% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -988.081% |
| IGM Biosciences, Inc. | 423.41 Million USD | -338.189% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -1159.926% |
| Acelyrin, Inc. | 742.69 Million USD | -149.814% |
| Abeona Therapeutics Inc. | 64 Million USD | -2798.881% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | -122.713% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -12689.599% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -332.076% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -1003.228% |
| Senti Biosciences, Inc. | 119.48 Million USD | -1452.795% |
| Mesoblast Limited | 669.15 Million USD | -177.267% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -222.243% |
| ChromaDex Corporation | 54.96 Million USD | -3275.559% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -31495.019% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -667.612% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -23153.88% |
| Seer, Inc. | 436.26 Million USD | -325.275% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -444.411% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -19169.584% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -266.511% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -34398.736% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -147.369% |
| Celcuity Inc. | 191.21 Million USD | -870.269% |
| ContextLogic Inc. | 423 Million USD | -338.615% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -348.321% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -1049.979% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 83.716% |
| Amarin Corporation plc | 831.68 Million USD | -123.083% |
| AnaptysBio, Inc. | 452.38 Million USD | -310.121% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -7368.569% |
| Aptorum Group Limited | 20.64 Million USD | -8889.02% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -508.209% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | -142.353% |
| Ardelyx, Inc. | 297.57 Million USD | -523.479% |
| Celularity Inc. | 143.88 Million USD | -1189.426% |
| Omeros Corporation | 378.26 Million USD | -390.482% |
| Humacyte, Inc. | 128.22 Million USD | -1346.965% |
| Immunocore Holdings plc | 597 Million USD | -210.777% |
| IO Biotech, Inc. | 150.71 Million USD | -1131.002% |
| GT Biopharma, Inc. | 14.1 Million USD | -13050.06% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -631.458% |
| Summit Therapeutics Inc. | 202.94 Million USD | -814.191% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -22353.612% |
| Pulmatrix, Inc. | 33.95 Million USD | -5363.637% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -42.611% |
| Evogene Ltd. | 51.1 Million USD | -3530.735% |
| CorMedix Inc. | 82.05 Million USD | -2160.959% |
| BioLineRx Ltd. | 63.92 Million USD | -2802.373% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -1400.442% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -1818.281% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 2.514% |
| scPharmaceuticals Inc. | 94.47 Million USD | -1863.761% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -619.979% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -198.518% |
| NLS Pharmaceutics AG | 1.84 Million USD | -100371.18% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -9704.343% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -219.737% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -1579.514% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -3292.222% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -712.528% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -1626.928% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -5643.915% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -10181.775% |
| Daré Bioscience, Inc. | 21.28 Million USD | -8617.805% |
| bluebird bio, Inc. | 619.16 Million USD | -199.654% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 72.881% |
| DBV Technologies S.A. | 182.98 Million USD | -913.926% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -195.176% |
| Galecto, Inc. | 38.22 Million USD | -4753.486% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -2394.611% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -1684.909% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -502.593% |
| GlycoMimetics, Inc. | 45.31 Million USD | -3994.189% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -443.507% |
| ADMA Biologics, Inc. | 329.18 Million USD | -463.622% |
| Clene Inc. | 52.34 Million USD | -3444.72% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -183.822% |
| Aptose Biosciences Inc. | 12.92 Million USD | -14257.405% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -8289.79% |
| Soligenix, Inc. | 9.79 Million USD | -18837.228% |
| Century Therapeutics, Inc. | 360.69 Million USD | -414.385% |
| Kura Oncology, Inc. | 448.93 Million USD | -313.276% |
| Surrozen, Inc. | 46.08 Million USD | -3926.35% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -581.738% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -1572.816% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -804.379% |
| Autolus Therapeutics plc | 375.38 Million USD | -394.256% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -637.312% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -3676.24% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -320.743% |
| GRI Bio, Inc. | 2.95 Million USD | -62665.291% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -17394.601% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -387.726% |
| INmune Bio, Inc. | 57 Million USD | -3154.929% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -733.839% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -2110.286% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -7004.002% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -15778.487% |
| Jaguar Health, Inc. | 50.76 Million USD | -3554.91% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -26854.663% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -2366.357% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -5354.001% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -1021.025% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -194.684% |
| Verastem, Inc. | 149.71 Million USD | -1139.224% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -262.263% |
| Histogen Inc. | 19.07 Million USD | -9627.583% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -8091.292% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -147.724% |
| Surrozen, Inc. | 46.08 Million USD | -3926.35% |
| Organovo Holdings, Inc. | 6.34 Million USD | -29122.586% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -42961.166% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -21678.232% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -411.157% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -10153.682% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -14611.253% |
| Kronos Bio, Inc. | 213.27 Million USD | -769.913% |
| Turnstone Biologics Corp. | 112.81 Million USD | -1544.588% |
| Synaptogenix, Inc. | 31.11 Million USD | -5863.109% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -15127.692% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -295.433% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -238.528% |
| Exelixis, Inc. | 2.94 Billion USD | 36.944% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -408.956% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | -135.232% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -1845.211% |
| ESSA Pharma Inc. | 149.12 Million USD | -1144.176% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -10286.933% |
| Avid Bioservices, Inc. | 336.55 Million USD | -451.271% |
| Insmed Incorporated | 1.32 Billion USD | -39.516% |
| MediWound Ltd. | 66.45 Million USD | -2691.709% |
| OmniAb, Inc. | 401.98 Million USD | -361.545% |
| Alector, Inc. | 621.82 Million USD | -198.369% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -417.385% |
| Zai Lab Limited | 1.03 Billion USD | -79.036% |
| AlloVir, Inc. | 190.79 Million USD | -872.422% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -287.779% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -628.482% |
| Aura Biosciences, Inc. | 255.07 Million USD | -627.371% |
| Immunic, Inc. | 54.29 Million USD | -3316.899% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -596.91% |
| Veracyte, Inc. | 1.13 Billion USD | -63.061% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -15592.939% |
| FibroGen, Inc. | 423.52 Million USD | -338.067% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -52713.607% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -293.158% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -39070.292% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -34071.646% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -20971.459% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -258.552% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 57.419% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -688.152% |
| XBiotech Inc. | 227.24 Million USD | -716.457% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -1845.211% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -401.41% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -28876.136% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -1201.081% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -548.912% |
| Agenus Inc. | 313.91 Million USD | -491.037% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -1350.971% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -385.693% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | -24.435% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -408.533% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -258.895% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -9869.955% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -392.851% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -17215.064% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -8275.834% |
| Lantern Pharma Inc. | 43.64 Million USD | -4150.729% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -1373.733% |
| Ainos, Inc. | 31.84 Million USD | -5726.749% |
| Pluri Inc. | 39.52 Million USD | -4593.86% |
| Prothena Corporation plc | 696.38 Million USD | -166.426% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -556.489% |
| Rallybio Corporation | 115.62 Million USD | -1504.69% |
| Kodiak Sciences Inc. | 479.37 Million USD | -287.036% |
| Cue Biopharma, Inc. | 61.53 Million USD | -2915.345% |
| MeiraGTx Holdings plc | 458.16 Million USD | -304.948% |
| Annexon, Inc. | 297.67 Million USD | -523.28% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -1249.644% |
| Moderna, Inc. | 18.42 Billion USD | 89.931% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -5835.385% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -2607.343% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -76.826% |
| Immix Biopharma, Inc. | 19.92 Million USD | -9211.554% |
| CalciMedica, Inc. | 12.18 Million USD | -15126.442% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -510.802% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -496.506% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -574.795% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -228.205% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -6734.679% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -1325.114% |
| Nutriband Inc. | 7.51 Million USD | -24581.442% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -2249.902% |
| Vor Biopharma Inc. | 209.82 Million USD | -784.22% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 74.312% |
| Alkermes plc | 2.13 Billion USD | 13.148% |
| ProKidney Corp. | 420.55 Million USD | -341.168% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -3283.623% |
| Arcellx, Inc. | 825.13 Million USD | -124.854% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -239.57% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -360.878% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -6479.227% |
| Atai Life Sciences N.V. | 293.47 Million USD | -532.191% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -1037.343% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -1356.107% |
| MediciNova, Inc. | 66.26 Million USD | -2699.672% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -2009.59% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -41477.549% |
| GeoVax Labs, Inc. | 9.28 Million USD | -19885.977% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -215.408% |
| Biomea Fusion, Inc. | 199.92 Million USD | -828.01% |
| RenovoRx, Inc. | 1.46 Million USD | -126458.117% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -282.469% |
| Geron Corporation | 394.07 Million USD | -370.808% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -25263.527% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -445.864% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -1023.891% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -252.511% |
| Royalty Pharma plc | 16.38 Billion USD | 88.674% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -568.127% |
| Imunon, Inc. | 21.91 Million USD | -8364.897% |
| BioAtla, Inc. | 119.65 Million USD | -1450.537% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -188.618% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -1833.957% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -720.73% |
| Structure Therapeutics Inc. | 482.01 Million USD | -284.912% |
| 89bio, Inc. | 596.26 Million USD | -211.159% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -738.63% |
| aTyr Pharma, Inc. | 122.06 Million USD | -1419.937% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -1105.527% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -278.314% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -12140.375% |
| Akari Therapeutics, Plc | 4.35 Million USD | -42502.572% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -10789.862% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -7.043% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -708.678% |
| Liquidia Corporation | 120.43 Million USD | -1440.585% |
| Entera Bio Ltd. | 11.76 Million USD | -15670.013% |
| GH Research PLC | 226.3 Million USD | -719.859% |
| Vericel Corporation | 353.65 Million USD | -424.616% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -1184.854% |
| Xencor, Inc. | 952.69 Million USD | -94.747% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -23736.03% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -7004.002% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -22887.505% |
| Vaxcyte, Inc. | 1.4 Billion USD | -31.779% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | -92.304% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -186.124% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -60060.52% |
| Portage Biotech Inc. | 7.77 Million USD | -23750.649% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -41477.549% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -569.932% |
| OncoCyte Corporation | 74.89 Million USD | -2377.357% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -91150.157% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -31962.493% |
| Purple Biotech Ltd. | 44.3 Million USD | -4087.942% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -3495.415% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -3996.853% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -457.587% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -5336.74% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -4754.756% |
| United Therapeutics Corporation | 7.16 Billion USD | 74.113% |
| HilleVax, Inc. | 344.43 Million USD | -438.664% |
| Silo Pharma, Inc. | 7.74 Million USD | -23851.823% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -38765.358% |
| Pharming Group N.V. | 462.85 Million USD | -300.848% |
| Tharimmune, Inc. | 10.94 Million USD | -16849.346% |
| Genprex, Inc. | 10.67 Million USD | -17287.433% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -362.213% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -273.914% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -967.97% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -76377.411% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -44441.31% |
| OKYO Pharma Limited | 1.54 Million USD | -120277.95% |
| Savara Inc. | 177.56 Million USD | -944.886% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -5625.304% |
| Curis, Inc. | 77.28 Million USD | -2300.743% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -2801.293% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -9477.936% |
| BeiGene, Ltd. | 5.8 Billion USD | 68.04% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -418.323% |
| Erasca, Inc. | 395.29 Million USD | -369.354% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -42814.264% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -42814.264% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -10084.674% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -15913.654% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -1241.874% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -298.461% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -491.935% |
| Adicet Bio, Inc. | 207.29 Million USD | -795.025% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -138.513% |
| Aditxt, Inc. | 44.57 Million USD | -4061.982% |
| Adagene Inc. | 115.72 Million USD | -1503.18% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -41553.868% |
| Quantum-Si incorporated | 298.25 Million USD | -522.076% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -23966.836% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -428.165% |
| Compugen Ltd. | 121.33 Million USD | -1429.12% |
| Generation Bio Co. | 374.75 Million USD | -395.077% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -628.539% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -1070.068% |
| Invivyd, Inc. | 229.18 Million USD | -709.553% |
| Relay Therapeutics, Inc. | 843.98 Million USD | -119.832% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -15146.085% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -917.239% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -8984.127% |
| 2seventy bio, Inc. | 565.42 Million USD | -228.132% |
| Instil Bio, Inc. | 325.63 Million USD | -469.77% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -3058.872% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -35648.966% |
| GeoVax Labs, Inc. | 9.28 Million USD | -19885.977% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -1690.678% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -1801.9% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -664.922% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 5.344% |
| Evaxion Biotech A/S | 12.88 Million USD | -14295.196% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -636.072% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -146.495% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -721.468% |
| Cingulate Inc. | 3.49 Million USD | -53039.797% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -11057.267% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -2724.39% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -1373.757% |
| Clearmind Medicine Inc. | 4.32 Million USD | -42804.142% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -1061.156% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -21573.012% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -403.499% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -189.65% |
| ImmunityBio, Inc. | 504.45 Million USD | -267.794% |
| Korro Bio, Inc. | 221.66 Million USD | -737.01% |
| Kineta, Inc. | 10.28 Million USD | -17946.318% |
| BioVie Inc. | 25.2 Million USD | -7260.031% |
| Codexis, Inc. | 136.56 Million USD | -1258.618% |
| Celularity Inc. | 143.88 Million USD | -1189.426% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -1455.373% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -192.018% |
| Virax Biolabs Group Limited | 5.48 Million USD | -33732.102% |
| Cibus, Inc. | 544.41 Million USD | -240.798% |
| IN8bio, Inc. | 33.7 Million USD | -5403.996% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -972.39% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -8737.908% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 37.95% |
| Eyenovia, Inc. | 28.77 Million USD | -6346.777% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -704.823% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -25583.029% |
| Elevation Oncology, Inc. | 89.09 Million USD | -1982.525% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -2945.238% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -2172.673% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -301.35% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -5933.633% |
| Moolec Science SA | 24.05 Million USD | -7614.106% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -498.256% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -1724.149% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -211.839% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -1082.688% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -26424.533% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -15326.068% |
| Humacyte, Inc. | 128.22 Million USD | -1346.965% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -635.803% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -100188.757% |
| Genelux Corporation | 27.89 Million USD | -6551.64% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -1975.257% |
| Notable Labs, Ltd. | 19.54 Million USD | -9394.611% |
| Immunovant, Inc. | 666.71 Million USD | -178.282% |
| Quantum-Si incorporated | 298.25 Million USD | -522.076% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -3325.668% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -956.898% |
| Acasti Pharma Inc. | 73.3 Million USD | -2431.162% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -40656.315% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -926.804% |
| PepGen Inc. | 143.05 Million USD | -1196.97% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -9570.795% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -31495.019% |
| Immuneering Corporation | 102.58 Million USD | -1708.598% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -42961.166% |
| Belite Bio, Inc | 94.64 Million USD | -1860.379% |
| XOMA Corporation | 234.3 Million USD | -691.863% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -695.642% |
| Bionomics Limited | 27.64 Million USD | -6610.318% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -1627.7% |
| uniQure N.V. | 831.68 Million USD | -123.081% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -41553.868% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -577.416% |
| Forte Biosciences, Inc. | 38.98 Million USD | -4659.728% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -45450.947% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -4937.447% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -25583.029% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -52713.607% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -15595.305% |
| Altimmune, Inc. | 210.64 Million USD | -780.812% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -884.496% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -1627.7% |
| Peak Bio, Inc. | 2.59 Million USD | -71357.837% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -976.64% |
| Benitec Biopharma Inc. | 52.21 Million USD | -3453.614% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -442.721% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -5235.582% |
| Zura Bio Limited | 100.84 Million USD | -1739.832% |
| PolyPid Ltd. | 15.37 Million USD | -11969.62% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -5235.582% |
| argenx SE | 4.54 Billion USD | 59.156% |
| Immunome, Inc. | 148.54 Million USD | -1149.052% |
| Verona Pharma plc | 308.12 Million USD | -502.141% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -2033.582% |
| Shattuck Labs, Inc. | 159.56 Million USD | -1062.757% |
| CervoMed Inc. | 9.97 Million USD | -18504.543% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -16192.079% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -934.164% |
| Moolec Science SA | 24.05 Million USD | -7614.106% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -30228.534% |
| Design Therapeutics, Inc. | 289.64 Million USD | -540.562% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -2447.672% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -34144.038% |
| Achilles Therapeutics plc | 161.45 Million USD | -1049.132% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -21573.012% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -830.925% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -2334.449% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -3103.505% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -252.365% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -782.257% |
| Beam Therapeutics Inc. | 1.45 Billion USD | -27.103% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -186.929% |
| AEON Biopharma, Inc. | 6.84 Million USD | -27005.069% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -1301.072% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -582.445% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -13430.919% |
| NeurAxis, Inc. | 509.49 Thousand USD | -364050.988% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -137.757% |
| Lumos Pharma, Inc. | 40.63 Million USD | -4465.535% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -2534.389% |
| Palisade Bio, Inc. | 14.05 Million USD | -13103.402% |
| Nutriband Inc. | 7.51 Million USD | -24581.442% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -594.9% |
| Neurogene Inc. | 222.57 Million USD | -733.588% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -29815.221% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -309.535% |
| Athira Pharma, Inc. | 160.24 Million USD | -1057.816% |
| HCW Biologics Inc. | 28.51 Million USD | -6406.853% |
| XOMA Corporation | 234.3 Million USD | -691.863% |
| Nektar Therapeutics | 398.03 Million USD | -366.128% |
| Arvinas, Inc. | 1.3 Billion USD | -42.215% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -10789.862% |
| Merus N.V. | 458.49 Million USD | -304.66% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -807.853% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -929.579% |
| Rezolute, Inc. | 132.73 Million USD | -1297.758% |
| Clene Inc. | 52.34 Million USD | -3444.72% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -12332.037% |
| BeyondSpring Inc. | 24.8 Million USD | -7378.805% |
| Synlogic, Inc. | 75.55 Million USD | -2355.78% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -15541.055% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -19713.563% |
| Peak Bio, Inc. | 2.59 Million USD | -71357.837% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -961.208% |
| Krystal Biotech, Inc. | 818.35 Million USD | -126.716% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -671.651% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -155.631% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -51766.138% |
| MannKind Corporation | 475.19 Million USD | -290.436% |
| Ikena Oncology, Inc. | 192.09 Million USD | -865.861% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -13772.753% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -1492.035% |
| Gossamer Bio, Inc. | 311.91 Million USD | -494.821% |
| CohBar, Inc. | 16.36 Million USD | -11236.794% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -5176.404% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -25263.527% |
| Legend Biotech Corporation | 1.84 Billion USD | -0.364% |
| Mural Oncology plc | 301.74 Million USD | -514.871% |
| Disc Medicine, Inc. | 367.99 Million USD | -404.175% |
| Champions Oncology, Inc. | 26.13 Million USD | -6999.885% |
| REGENXBIO Inc. | 573.97 Million USD | -223.247% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -68411.217% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -1101.755% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -15264.413% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -445.633% |
| Vaxart, Inc. | 91.83 Million USD | -1920.409% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -2997.198% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -1150.847% |
| Cellectis S.A. | 334.27 Million USD | -455.043% |
| Longeveron Inc. | 12.17 Million USD | -15135.195% |
| Repare Therapeutics Inc. | 253.9 Million USD | -630.734% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 43.167% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -823.759% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 11.168% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -114074.892% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -568.084% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -1037.563% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -1237.241% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -7169.579% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 91.838% |
| Denali Therapeutics Inc. | 1.15 Billion USD | -60.786% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -15092.02% |
| Veru Inc. | 50.59 Million USD | -3566.979% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -3972.93% |
| Cingulate Inc. | 3.49 Million USD | -53039.797% |
| Passage Bio, Inc. | 150.54 Million USD | -1132.417% |
| Context Therapeutics Inc. | 16.06 Million USD | -11450.598% |
| Exicure, Inc. | 11.58 Million USD | -15921.952% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -393.379% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -1047.809% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -10518.945% |
| Nuvalent, Inc. | 732.38 Million USD | -153.329% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -12315.231% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -1971.758% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -12974.075% |
| OmniAb, Inc. | 401.98 Million USD | -361.545% |
| Anew Medical, Inc. | 19.45 Million USD | -9436.115% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -6841.942% |
| Lipocine Inc. | 23 Million USD | -7966.328% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -1227.074% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -507.184% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -2110.286% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -1426.528% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -23281.752% |
| Sage Therapeutics, Inc. | 882.27 Million USD | -110.29% |
| Ocugen, Inc. | 64.54 Million USD | -2774.405% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -1389.744% |
| Q32 Bio Inc. | 306.11 Million USD | -506.085% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -43990.827% |
| Alumis Inc. Common Stock | 89.61 Million USD | -1970.417% |
| Equillium, Inc. | 50.53 Million USD | -3571.763% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -2367.374% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -4395.235% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -108983.031% |
| Dominari Holdings Inc. | 57.55 Million USD | -3123.43% |
| Edesa Biotech, Inc. | 8.89 Million USD | -20768.963% |
| vTv Therapeutics Inc. | 11.01 Million USD | -16739.19% |
| Bio-Techne Corporation | 2.81 Billion USD | 34.048% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -97.984% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | -128.646% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -568.194% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -4349.048% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -177.917% |
| Nkarta, Inc. | 378.88 Million USD | -389.685% |
| BioCardia, Inc. | 2.98 Million USD | -62013.894% |
| Iterum Therapeutics plc | 26.25 Million USD | -6965.547% |